RxDoctor Payments Data

Sergio Rodarte, MD

Psychiatry · El Paso, TXNPI 1518172105

Payments from drug & device makers

$4,380in general payments, 2019–2025

Across 274 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$791
  • Neurocrine Biosciences, Inc.$760
  • Teva Pharmaceuticals USA, Inc.$629
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$429
  • Alkermes, Inc.$339
  • AbbVie$275
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$4,12594%
  • Education$2556%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,380 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$13,382
Medicare patients
71
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate59$586,960
Invega SustennaPaliperidone Palmitate137$290,545
AustedoDeutetrabenazine30$133,168
Invega TrinzaPaliperidone Palmitate13$104,683
RexultiBrexpiprazole56$87,089
VraylarCariprazine Hcl37$59,613
Abilify MaintenaAripiprazole14$43,255
Paliperidone ErPaliperidone92$37,402
Lurasidone Hcl73$28,477
VivitrolNaltrexone Microspheres13$21,397
Oxcarbazepine236$15,167
TrintellixVortioxetine Hydrobromide25$12,746
FetzimaLevomilnacipran Hcl22$10,961
Clozapine102$10,034
Quetiapine Fumarate430$9,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$760$586,96059 claims
Johnson & JohnsonInvega Sustenna, Invega Trinza$126$395,228150 claims
Teva Pharmaceuticals USA, Inc.Austedo$629$133,16830 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$274$130,34470 claims
AbbVieVraylar, Fetzima$275$70,57459 claims
Alkermes, Inc.Vivitrol$339$21,39713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →